These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 29651744)

  • 61. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [CAR T-cell therapy: Balance of efficacy and safety].
    Kulemzin SV; Kuznetsova VV; Mamonkin M; Taranin AV; Gorchakov AA
    Mol Biol (Mosk); 2017; 51(2):274-287. PubMed ID: 28537234
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
    Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
    Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
    Atanackovic D; Radhakrishnan SV; Bhardwaj N; Luetkens T
    Br J Haematol; 2016 Mar; 172(5):685-98. PubMed ID: 26791002
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.
    Pang Y; Hou X; Yang C; Liu Y; Jiang G
    Mol Cancer; 2018 May; 17(1):91. PubMed ID: 29769134
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.
    Xu XJ; Song DG; Poussin M; Ye Q; Sharma P; Rodríguez-García A; Tang YM; Powell DJ
    Oncotarget; 2016 Dec; 7(50):82354-82368. PubMed ID: 27409425
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer.
    Leong L; Tan HL; Cua S; Yong KSM; Chen Q; Choo A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936170
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.
    Ang WX; Li Z; Chi Z; Du SH; Chen C; Tay JC; Toh HC; Connolly JE; Xu XH; Wang S
    Oncotarget; 2017 Feb; 8(8):13545-13559. PubMed ID: 28088790
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
    Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
    Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
    Hardaway JC; Prince E; Arepally A; Katz SC
    J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
    [No Abstract]   [Full Text] [Related]  

  • 73. New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.
    Wang J; Zhou P
    Adv Exp Med Biol; 2017; 1026():371-381. PubMed ID: 29282693
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Chimeric antigen receptor-modified T cells strike back.
    Frigault MJ; Maus MV
    Int Immunol; 2016 Jul; 28(7):355-63. PubMed ID: 27021308
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH; Stashwick C; Plesa G; Tanyi JL
    Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
    Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
    Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 78. L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.
    Hong H; Brown CE; Ostberg JR; Priceman SJ; Chang WC; Weng L; Lin P; Wakabayashi MT; Jensen MC; Forman SJ
    PLoS One; 2016; 11(1):e0146885. PubMed ID: 26761817
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.
    Genta S; Ghisoni E; Giannone G; Mittica G; Valabrega G
    Expert Opin Biol Ther; 2018 Apr; 18(4):359-367. PubMed ID: 29307234
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.